Canagliflozin (Type 2 Diabetes) - Analysis and Forecasts to 2020
NEW YORK, Oct. 18, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Canagliflozin (Type 2 Diabetes) – Analysis and Forecasts to 2020
http://www.reportlinker.com/p0657149/Canagliflozin-Type-2-Diabetes-–-Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Canagliflozin (Type 2 Diabetes) – Analysis and Forecasts to 2020
Summary
GlobalData's pharmaceuticals report, "Canagliflozin (Type 2 Diabetes) – Analysis and Forecasts to 2020" provides Canagliflozin sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Note: This is a on-demand report and will be delivered within 2 business days (excluding weekends) of the purchase.
Scope
- Therapy area profile including patient population for the US, EU% and Japan (seven major markets)
- Analysis and review of Canagliflozin
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Canagliflozin including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2013-2020 for Canagliflozin in the US, EU5 and Japan
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 4
2 Introduction 5
2.1 Diabetes 5
2.2 Epidemiology 5
2.2.1 Prevalence 5
2.2.2 Mortality 7
2.3 Etiology and Risk Factors 9
2.3.1 Obesity 9
2.3.2 Sedentary Lifestyle 9
2.3.3 Family History and Genetics 9
2.3.4 Ethnicity 9
2.3.5 Old Age 9
2.4 Economic Impact of Diabetes 9
2.5 GlobalData Report Guidance 11
3 Type 2 Diabetes: Market Characterization 12
3.1 Type 2 Diabetes Market 12
3.2 Type 2 Diabetes Market Forecasts 13
3.3 Type 2 Diabetes Market: Drivers and Restraints 14
3.3.1 Drivers 14
3.3.2 Restraints 15
4 Classification of Diabetes 16
4.1 Types of Diabetes 16
4.1.1 Type 1 Diabetes 16
4.1.2 Type 2 Diabetes 16
4.1.3 Gestational Diabetes 16
4.2 Diabetes Complications 16
4.2.1 Cardiovascular Disease 16
4.2.2 Nephropathy 17
4.2.3 Neuropathy 17
4.2.4 Amputation 17
4.2.5 Retinopathy 17
5 Evolution of Anti-Diabetic Treatments 18
6 Medications 19
6.1 Insulin 19
6.2 Oral Medications 19
6.2.1 Sulfonylureas (SUR) 19
6.2.2 Biguanides (BGDs) 20
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21
6.2.4 Meglitinides 21
6.2.5 Thiazolidinediones (TZDs) 22
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 23
6.2.7 Oral Combination Therapy 23
6.3 Other Injectionable Medications 24
6.3.1 Pramlintide 24
6.3.2 Exenatide 24
6.4 Market Share as per Classes in Type 2 Diabetes 24
7 Canagliflozin 25
7.1 Introduction 25
7.2 Mechanism of Action 25
7.3 Clinical Studies 25
7.3.1 A Phase II Trial Evaluating Canagliflozin Vs Januvia for the Treatment of NIDDM Patients 25
7.3.2 A Phase III Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Canagliflozin Compared with Amaryl for the Treatment of Type 2 Diabetes 25
7.3.3 A Phase III Clinical Trial Evaluating Canagliflozin as a Monotherapy in Type 2 Diabetes Non Insulin Diabetes Mellitus Patients 26
7.4 Factors Affecting Sales of Canagliflozin 26
7.4.1 Emergence of SGLT2 inhibitors 26
7.4.2 No Weight Gain 26
7.5 Drug Evaluation 26
7.5.1 Drug Risk Benefit Score 26
7.5.2 Intensity of Competition 27
7.6 Sales Forecasts 28
7.6.1 Dosing 28
7.6.2 Market Penetration 28
7.6.3 Annual Cost of Therapy 28
7.6.4 Sales Projections of Canagliflozin 29
8 Diabetes Market: Appendix 38
8.1 Market Definitions 38
8.2 List of Abbreviations 38
8.3 Research Methodology 38
8.3.1 Coverage 39
8.3.2 Secondary Research 39
8.3.3 Forecasting 39
8.3.4 Net Penetration of Drug 40
8.3.5 Net Annual Dosing 40
8.3.6 Annual Cost of Therapy 40
8.3.7 Primary Research 40
8.3.8 Expert Panels 40
8.4 Drug Sales Estimates Model 41
8.5 Contact Us 41
8.6 Disclaimer 41
8.7 Sources 41
1.1 List of Tables
Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
Table 4: Type 2 Diabetes, World, Major Marketed Drugs, 2010 12
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 13
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
Table 8: Diabetes Drugs Evolution 18
Table 9: Drug Risk Benefit Score of Canagliflozin 26
Table 10: Canagliflozin, Type 2 Diabetes, Global, Sales Forecasts ($m), 2013–2020 29
Table 11: Canagliflozin, Type 2 Diabetes, The US, Sales Forecasts ($m), 2013–2020 30
Table 12: Canagliflozin, Type 2 Diabetes, The UK, Sales Forecasts ($m), 2013–2020 31
Table 13: Canagliflozin, Type 2 Diabetes, France, Sales Forecasts ($m), 2013–2020 32
Table 14: Canagliflozin, Type 2 Diabetes, Germany, Sales Forecasts ($m), 2013–2020 33
Table 15: Canagliflozin, Type 2 Diabetes, Italy, Sales Forecasts ($m), 2013–2020 34
Table 16: Canagliflozin, Type 2 Diabetes, Spain, Sales Forecasts ($m), 2013–2020 35
Table 17: Canagliflozin, Type 2 Diabetes, Japan, Sales Forecasts ($m), 2016–2020 36
1.2 List of Figures
Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6
Figure 3: Diabetes, World, Mortality, 2010 7
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 2010–2020 13
Figure 6: Mechanism of Action of Sulfonylurea 19
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 20
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 21
Figure 9: Mechanism of Action of Thiazolidinediones 22
Figure 10: Mechanism of Action of DPP IV Inhibitors 23
Figure 11: Type 2 Diabetes, Global, Market Share by Value, By Class (%), 2010 24
Figure 12: Canagliflozin, Type 2 Diabetes, Global, Sales Forecasts ($m), 2013–2020 29
Figure 13: Canagliflozin, Type 2 Diabetes, The US, Sales Forecasts ($m), 2013–2020 30
Figure 14: Canagliflozin, Type 2 Diabetes, The UK, Sales Forecasts ($m), 2013–2020 31
Figure 15: Canagliflozin, Type 2 Diabetes, France, Sales Forecasts ($m), 2013–2020 32
Figure 16: Canagliflozin, Type 2 Diabetes, Germany, Sales Forecasts ($m), 2013–2020 33
Figure 17: Canagliflozin, Type 2 Diabetes, Italy, Sales Forecasts ($m), 2013–2020 34
Figure 18: Canagliflozin, Type 2 Diabetes, Spain, Sales Forecasts ($m), 2013–2020 35
Figure 19: Canagliflozin, Type 2 Diabetes, Japan, Sales Forecasts ($m), 2016–2020 36
Figure 20: Canagliflozin, Type 2 Diabetes, Sales Distribution by Country (%), 2020 37
To order this report:
Pathology Industry: Canagliflozin (Type 2 Diabetes) – Analysis and Forecasts to 2020
Pathology Business News
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article